5328512025-04-012025-06-305328512025-04-012025-06-30in-capmkt:OtherExpenses1Member5328512025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15328512025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25328512025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35328512025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss45328512025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532851INSECTICIDNAINE070I01018Insecticides (India) LimitedMain BoardEquity2025-04-012026-03-312025-08-132025-06-26INRLakhsQuarterlyFirst quarterSingle segmentAgro-Chemicals2025-08-1313:00:002025-08-1314:30:00Not applicable2025-04-012025-06-30UnauditedConsolidated69113310003705700069483880003728776000451041000715009000415252000372260007312800075540200061758340007725540000772554000187159000632200019348100005790730000001981000581054000-54600058050800000002909780001019.9719.970019.9719.970001. The above Unaudited Consolidated Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended. The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on August 13 2025. The Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com www.nseindia.com and on the Companys website www.insecticidesindia.com. 2.The above Unaudited Consolidated Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS) the provisions of the Companies Act 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and subsequent amendments thereto. 3.The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz Agro-Chemicals comprising of Technical & Formulation. 4.The Board of Directors of Insecticides (India) Limited at its meeting held on August 09 2024 had approved the dissolution/ liquidation of its wholly owned subsidiary IIL Overseas DMCC Dubai. Accordingly IIL Overseas DMCC has filed the application for windup / dissolution with DMCCA (Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority) for which approval is yet to be received as of June 30 2025. 5.The figures of the quarter ended March 31 2025 are the balancing figures between the audited figures in respect of the full financial year up to 31 March 2025 and the unaudited published year-to-date figures up to 31 December 2024 being the date of the end of the third quarter of the financial year which were subjected to a limited review. 6.The Board of Directors of the Company at its meeting held on November 11 2024 approved the acquisition of 100% equity shares of Kaeros Research Limited (formerly know as Kaeros Research Private LImited (Target Company) from its existing shareholders through a share purchase agreement (SPA) between the existing shareholders and the Company. Consequently target company becomes the wholly owned subsidiary of the Group. The transaction is considered as Common control transaction as per Ind AS 103. As per guidance on accounting for common control transactions contained in Ind AS 103 Business Combinations the acquisition has been accounted for using the pooling of interest method. Accordingly the consolidated financial statements of the Group have been restated with effect from April 01 2023 by transferring all assets liabilities and reserves of the target company with the differential amount from the purchase consideration has been recognised in capital reserve (other equity). Therefore the figures for the quarter ended June 30 2024 have been restated.Other Expenses755402000Changes in fair value of FVTOCI equity instruments2709000Remeasurement of net defined benefit plans-3500000Share of Other comprehensive income of joint venture accounted for using equity method12000Income tax relating to these items247000-5320000Exchange differences in translating the financial statements of foreign operations-14000-140000-546000